Clinical Trial Update: Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating low-dose viloxazine extended-release for attention deficit/hyperactivity disorder in children has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Viloxazine extended-release capsule (viloxazine)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: ADHD | Phase 3 | Status: COMPLETED | Results posted: 2021-06-02